(Q36808057)

16 August 2017

1 reference

title

Donepezil: an update (English)

1 reference

16 August 2017

1

Ben Seltzer

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Expert Opinion on Pharmacotherapy

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

1011-1023

1 reference

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Donepezil: a clinical review of current and emerging indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

The magnitude of dementia occurrence in the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Molecular biology and genetics of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Immunology and immunotherapy of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Development of BACE1 inhibitors for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Global change assessments in anti-Alzheimer clinical drug trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Regulatory aspects of vascular dementia in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Cholinergic markers in elderly patients with early signs of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Cholinergic treatment: what are the early neuropathological targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Acetylcholinesterase imaging: its use in therapy evaluation and drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Peripheral cytokine release in Alzheimer patients: correlation with disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Observations on the brains of demented old people

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Donepezil in vascular dementia: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Donepezil in vascular dementia: combined analysis of two large-scale clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Classification of vascular dementia in the Cardiovascular Health Study Cognition Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

In vivo cholinergic circuit evaluation in frontotemporal and Alzheimer dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Rivastigmine in frontotemporal dementia: an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Effects of Donepezil on Cognitive Functioning in Down Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Effects of donepezil on memory and cognition in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Efficacy and tolerability of low-dose donepezil in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Impact of donepezil treatment for Alzheimer's disease on caregiver time

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Economic evaluation of donepezil in moderate to severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

A Large, Community-Based, Open-Label Trial of Donepezil in the Treatment of Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Donepezil for Alzheimer's disease in clinical practice--The DONALD Study. A multicenter 24-week clinical trial in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Cholinergic enhancement of frontal lobe activity in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

The safety and tolerability of donepezil in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Galantamine extended release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1011

10.1517/14656566.8.7.1011

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference